NEWTOWN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter ended March 31, 2024.
First Quarter and Recent Business Updates
- Received Healthcare Common Procedure Coding System (“HCPCS”) codes and preliminary determination for reimbursement for the Portable Neuromodulation Stimulator (“PoNS®”) mouthpiece and controller from the Centers for Medicare & Medicaid Services (“CMS”), paving the way toward final price determination on October 1, 2024.
- Added six more sites to the stroke registrational program in the U.S. and Canada; reached alignment with the U.S. Food and Drug Administration (“FDA”) on optimizing the stroke development plan.
- Announced partnership with Lovell® Government Services to make PoNS available to federal healthcare systems, including the U.S. Department of Veterans Affairs (“VA”) and Department of Defense (“DoD”).
- Q1 2024 revenue of $135 thousand, compared to $111 thousand in Q1 2023, reflecting increased product sales in both the U.S. and Canada.
- Closed on $6.4 million public offering, raising net proceeds of approximately $5.6 million.
“We marched one step closer to an important milestone when CMS released its preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece earlier this month. This was a significant achievement for Helius, and at the HCPCS public meeting later this month, we will present arguments to support higher reimbursement rates than those established in the preliminary determinations. Once the reimbursement amount is finalized, the payment rates are expected to be effective October 1,” stated Helius’ President and Chief Executive Officer, Dane Andreeff.
“We believe the establishment of Medicare payment rates will make it easier to expand reimbursement across third-party payers, creating a pathway to positive cash flow as we continue pursuing stroke authorization in the U.S. We remain on track for an early 2025 regulatory submission for stroke, and we added several new sites to our registrational program during the quarter to advance this objective. It’s an exciting time at Helius with the achievement of two monumental goals in sight and the cash that will help us get there,” concluded Andreeff.
First Quarter 2024 Financial Results
Total revenue for the first quarter of 2024 was $135 thousand, an increase of $24 thousand compared to $111 thousand in the first quarter of 2023, primarily attributable to higher product sales in the U.S. and Canada.
Cost of revenue was $123 thousand for the three months ended March 31, 2024, compared to $122 thousand for the comparable period in 2023, remaining relatively flat due to fixed overhead costs.
Operating expenses for the first quarter of 2024 decreased to $3.4 million, compared to $3.8 million in the first quarter of 2023. The decrease was driven primarily by a decrease in professional fees and payroll related expenses as well as in product development expenses and clinical trial activities as we transitioned our focus in the U.S. to commercialization activities. This decrease was partially offset by an increase in contract manufacturer expense associated with the transition to a new contract manufacturer during the current year period.
Operating loss for the first quarter of 2024 decreased $0.4 million to a loss of $3.4 million, compared to an operating loss of $3.8 million in the first quarter of 2023.
Net loss was $2.5 million in the first quarter of 2024 and in the corresponding prior year period. The basic and diluted net loss per share for the first quarter was $3.08 per share compared to a net loss of $4.42 per share for the first quarter of 2023.
Cash and Liquidity
Cash used in operating activities for the three months ended March 31, 2024, was $3.0 million compared to $3.2 million in the first quarter of 2023.
As of March 31, 2024, the Company had cash of $3.6 million and no debt outstanding. On May 9, 2024, the Company raised $5.6 million in net proceeds in a public offering, extending the cash runway into 2025.
Conference Call
| Date: | Monday, May 13, 2024 |
| Time: | 4:30 p.m. Eastern Time |
| Register (Audio only): | Click Here |
| Webcast: | Click Here |
The webcast will be archived under the Newsroom section of the Company’s investor relations website.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using orally applied technology platform that amplifies the brain’s ability to engage physiologic compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator. For more information about the PoNS® or Helius Medical Technologies, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation through a mouthpiece connected to a controller and it’s used, primarily at home, with physical rehabilitation exercise, to improve balance and gait. The PoNS device, which delivers mild electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.
PoNS has shown effectiveness in treating gait or balance and a significant reduction in the risk of falling in stroke patients in Canada, where it received authorization for sale in three indications: (i) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from stroke and is to be used in conjunction with physical therapy; (ii) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (iii) for use as a short-term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait. For more information visit www.ponstherapy.com.
Cautionary Disclaimer Statement
Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believe,” “expect,” “continue,” “will,” “goal,” “aim” and similar expressions. Such forward-looking statements include, among others, statements regarding the sufficiency of the Company’s future cash position, the development, commercialization and success of the Company’s PoNS and PoNS Treatment, future decisions and approvals from applicable regulatory entities in the U.S. and Canada, the Company’s strategic operating plans, and the uses and effectiveness of PoNS and PoNS Therapy.
There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include uncertainties associated with the Company’s capital requirements to achieve its business objectives, availability of funds, the Company’s ability to find additional sources of funding, manufacturing, labor shortage and supply chain risks, including risks related to manufacturing delays, the Company’s ability to obtain national Medicare insurance coverage and to obtain a reimbursement code, the Company’s ability to continue to build internal commercial infrastructure, secure state distribution licenses, market awareness of the PoNS device, future clinical trials and the clinical development process, the product development process and the FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.
The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.
Investor Relations Contact
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
| Helius Medical Technologies, Inc. | ||||||||
| Unaudited Condensed Consolidated Statements of Operations | ||||||||
| (in thousands, except share and per share data) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenue | ||||||||
| Product sales, net | $ | 124 | $ | 106 | ||||
| Other revenue | 11 | 5 | ||||||
| Total revenue | 135 | 111 | ||||||
| Cost of revenue | 123 | 122 | ||||||
| Gross profit (loss) | 12 | (11 | ) | |||||
| Operating expenses | ||||||||
| Selling, general and administrative expenses | 2,633 | 2,874 | ||||||
| Research and development expenses | 788 | 886 | ||||||
| Amortization expense | 7 | 39 | ||||||
| Total operating expenses | 3,428 | 3,799 | ||||||
| Loss from operations | (3,416 | ) | (3,810 | ) | ||||
| Nonoperating income (expense) | ||||||||
| Interest income (expense), net | (8 | ) | 100 | |||||
| Change in fair value of derivative liability | 1,142 | 1,221 | ||||||
| Foreign exchange loss | (288 | ) | (5 | ) | ||||
| Other income, net | 54 | — | ||||||
| Nonoperating income, net | 900 | 1,316 | ||||||
| Loss before provision for income taxes | (2,516 | ) | (2,494 | ) | ||||
| Provision for income taxes | — | — | ||||||
| Net loss | $ | (2,516 | ) | $ | (2,494 | ) | ||
| Loss per share | ||||||||
| Basic | $ | (3.08 | ) | $ | (4.42 | ) | ||
| Diluted | $ | (3.08 | ) | $ | (4.42 | ) | ||
| Weighted average number of common shares outstanding | ||||||||
| Basic | 817,327 | 564,134 | ||||||
| Diluted | 817,327 | 564,134 | ||||||
| Helius Medical Technologies, Inc. | ||||||||
| Unaudited Condensed Consolidated Balance Sheets | ||||||||
| (in thousands, except share and per share data) | ||||||||
| March 31, 2024 | December 31, 2023 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 3,638 | $ | 5,182 | ||||
| Accounts receivable, net | 49 | 117 | ||||||
| Other receivables | 513 | 520 | ||||||
| Inventory, net | 384 | 457 | ||||||
| Prepaid expenses and other current assets | 940 | 1,162 | ||||||
| Total current assets | 5,524 | 7,438 | ||||||
| Property and equipment, net | 174 | 178 | ||||||
| Intangible assets, net | 17 | 24 | ||||||
| Operating lease right-of-use asset, net | 42 | 52 | ||||||
| Total assets | $ | 5,757 | $ | 7,692 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 814 | $ | 531 | ||||
| Accrued and other current liabilities | 674 | 1,260 | ||||||
| Current portion of operating lease liabilities | 46 | 45 | ||||||
| Current portion of deferred revenue | 42 | 43 | ||||||
| Total current liabilities | 1,576 | 1,879 | ||||||
| Operating lease liabilities, net of current portion | — | 12 | ||||||
| Deferred revenue, net of current portion | 115 | 128 | ||||||
| Derivative liability | 2,080 | 3,323 | ||||||
| Total liabilities | 3,771 | 5,342 | ||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Class A common stock, $0.001 par value; 150,000,000 shares authorized; 887,847 and 714,590 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 1 | 1 | ||||||
| Additional paid-in capital | 164,843 | 162,979 | ||||||
| Accumulated deficit | (162,473 | ) | (159,957 | ) | ||||
| Accumulated other comprehensive loss | (385 | ) | (673 | ) | ||||
| Total stockholders' equity | 1,986 | 2,350 | ||||||
| Total liabilities and stockholders' equity | $ | 5,757 | $ | 7,692 | ||||
